Oncotelic Therapeutics, Inc. (OTLC) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US6283411097

Price
0.01 USD
Market cap
4.58 m USD
P/E (2025)
0.02
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
94.87 %
Return on assets (ROA)
63.42 %

Oncotelic Therapeutics, Inc. financials

Fiscal year20242025
Operating income-3.58 m USD-3.19 m USD
EBIT-4.78 m USD360.57 m USD
Net income-4.52 m USD249.28 m USD
Diluted EPS – continuing operations-0.01 USD0.59 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.